USPTO serial 99288313
MYRANOVA
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- OBREGON, MICHAEL A
- Law office
- TTAB
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with MYRANOVA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Chungcheongbuk-do, KR
Chungcheongbuk-do, KR
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
MARK J. LISS
MARK J. LISS LEYDIG, VOIT & MAYER, LTD.180 N. STETSON AVENUESUITE 4900CHICAGO, IL 60601Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical agents affecting sensory organs; muscle relaxants; pharmaceutical agents affecting peripheral nervous system; pharmaceuticals containing botulinum toxin for medical use for use in the treatment of glabellar lines, forehead wrinkles, lateral canthal line, migraine headache, overactive bladder, urge incontinence, prostate disorder, cervical dystonia, spasticity, muscle dystonia, blepharospasm, hyperhidrosis, strabismus, excessive eye blinking, neuropathy pain and pelvic pain; pharmacological preparations for skin care; pharmaceutical syringes prefilled with medical botulinum toxin as the main ingredient for medical use for use in the treatment of glabellar lines, forehead wrinkles, lateral canthal line, migraine headache, overactive bladder, urge incontinence, prostate disorder, cervical dystonia, spasticity, muscle dystonia, blepharospasm, hyperhidrosis, strabismus, excessive eye blinking, neuropathy pain and pelvic pain; injectable dermal fillers; pharmaceutical preparations acting on the central nervous system; pain relief medication; dermatological pharmaceutical products | ABANDONED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 10, 2026 | MAB4 | ABANDONMENT NOTICE E-MAILED - INTER PARTES DECISION | — |
| Aug 10, 2026 | ABN4 | ABANDONMENT - AFTER INTER PARTES DECISION | — |
| Aug 10, 2026 | OP.T | OPPOSITION TERMINATED NO. 999999 | — |
| Aug 10, 2026 | OP.S | OPPOSITION SUSTAINED NO. 999999 | — |
| Jun 17, 2026 | ETOP | EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED | — |
| Jun 16, 2026 | OP.I | OPPOSITION INSTITUTED NO. 999999 | — |
| Mar 3, 2026 | ETOF | EXTENSION OF TIME TO OPPOSE RECEIVED | — |
| Feb 17, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Feb 17, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Feb 11, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jan 26, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jan 5, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jan 5, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 5, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 4, 2025 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 4, 2025 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 4, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 4, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 17, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 17, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jul 17, 2025 | NWAP | NEW APPLICATION ENTERED | — |